Roche Holding AG said Thursday that its crenezumab drug it is studying for the treatment of Alzheimer's disease didn't slow or prevent cognitive decline in patients in a trial.
The trial was conducted in cognitively unimpaired people who carry a specific genetic mutation which causes early-onset Alzheimer's disease, the Swiss pharma company said.
"The trial did not demonstrate a statistically significant clinical benefit in either of its co-primary endpoints assessing the rate of change in cognitive abilities or episodic memory function," Roche said.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.